Bob Hugin made hundreds of millions price-gouging cancer patients over the years. Now NJ.com is reporting that Bob Hugin’s company, Celgene, raised prices on American cancer patients while giving huge discounts to Russia.
“Celgene Corp. under Bob Hugin, the Republican running for U.S. Senate in New Jersey, raised U.S. prices by 20 percent for its Revlimid cancer drug while cutting them by 45 percent in Russia last year, documents show…
“Celgene under Hugin spent a record amount of money to help defeat legislation that would have made it easier for generic companies to get drug samples, and President Donald Trump’s Food and Drug Administration singled out the company for refusing to make those samples available to competitors.”
“Celgene’s pricing of the cancer drug Revlimid has come under attack by Trump and advocacy groups.
“The price of a 21-tablet supply of Revlimid in 25 mg dose was $14,529 in the United States, according to a report by Patients for Affordable Drugs Action, a super political action committee opposing Hugin.
“That same product cost $4,175 in Russia after the price reduction, according to the Russian Federation’s Federal Antimonopoly Service.”
New Jerseyans deserve a leader in the U.S. Senate who will stand up to greedy drug CEOs like Bob Hugin — not one who will work to further the interests of big pharmaceutical companies, Donald Trump, and the Kremlin.